The Alliance for Lupus Research (ALR) is committed to supporting research targeted to new or improved treatments for lupus.
Please see below for a list of new therapeutics for lupus currently in clinical trials. The ALR was directly supportive of many of the agents currently in the clinical pipeline (those marked with an asterisk). After decades with no new treatments, we are proud to have been a catalyst for this increased attention to lupus research and will continue our aggressive efforts until new therapies are brought to market.
New Lupus Therapeutics |
Drug Name |
Company |
| Anti-Interferon-alpha Therapy | Medi-545* rhuMab IFN Alpha* |
Medimmune Genentech |
| Anti-B cell therapy | Rituxan (anti-CD20)* - click here for an update Ocrelizumab* Epratuzumab* Belimumab* Atacicept (TACI-Ig)* LJP 394 TRU-015* |
Genentech Genentech Immunomedics, Inc. Human Genome Sciences EMD Serono LaJolla Pharmeceuticals Wyeth Pharmaceuticals |
| Anti-T cell therapy | Abatacept | Bristol-Myers Squibb |
| Anti-cytokine therapy | Tocilizumab Etanercept |
Chugai Pharmaceutical Company National Institute of Allergy and Infectious Diseases |
|
|
